Form D · Biotechnology
AMNIS CORP
Seattle, WA · CIK 0001108433
Offering snapshot reported Jul 29, 2009 · SEC filing
- Reported sold
- $894K Offering amount: $1.5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 24, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 29, 2009 | Initial | $893,675 | No comparison | 6 | SEC filing |
| Jan 9, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 13, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-62596
Source: Form D, filed Jul 29, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Basiji | Director, Executive |
| Annette Campbell White | Director |
| Carl Gordon | Director |
| Wei Wu Hu | Director |
| Pat Mc Dermott | Executive |
| William Ortyn | Director, Executive |
| David Perry | Executive |
| Richard L. Robb | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2505 Third Ave., Suite 210
Seattle, WA, 98121
Seattle, WA, 98121